Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Risk Assessment

View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Laboratorios Farmaceuticos Rovi is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Laboratorios Farmaceuticos Rovi's Risk Assessment

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laboratorios Farmaceuticos Rovi's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Risk Assessment falls into.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Laboratorios Farmaceuticos Rovi Risk Assessment Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

ROVI:Mexico ROVIe:UK 41L:Germany

Address

Julian Camarillo, 35, Madrid, ESP, 28037

Website

https://www.rovi.es

Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.